Emergent Biosolutions Acquires Monoclonal Anthrax Product Candidate
Acquisition represents important addition to company’s portfolio of anthrax countermeasures
Emergent BioSolutions Inc. (NYSE: EBS) announced that today it completed the acquisition of a group of anthrax monoclonal antibodies from AVANIR Pharmaceuticals (NASDAQ:AVNR), including Avanir’s lead product candidate, AVP-21D9.
AVP-21D9 is a human monoclonal antibody product candidate that is being developed as an intravenous treatment for patients [...]
July 13, 2009
Tags: Anthrax, Clinical trial, Infectious disease, Monoclonal antibodies, National Institute of Allergy and Infectious Diseases, NIAID, U.S. Food and Drug Administration, United States. Posted in: Uncategorized 
No Comments